European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020

A Review Study On Relationship Among Covid-19 And Pneumonia

Dr.Akila K[1], Dr.Senthil Nathan[2]

[1]*Assistant Professor, Meenakshi Academy of Higher Education and Research*
[2]*Assistant Professor, Meenakshi Academy of Higher Education and Research*

Email: [1]akila@mmchri.ac.in

ABSTRACT: First declared as a coronavirus disease by the World Health Organisation (WHO) in March 2020 (COVID-19), the number of Positive and death cases continues to rise even seven months after that. Seven months later. This global pandemic has had a huge effect on the world's health, social and economic facets. Therefore, it is necessary to recognise the risk factors that lead to the production of serious infections for risk stratification, to improve the re-allocation of hospital resources and to direct guidelines and strategies on public health. A variety of co-morbidity consequences such as hypertension, diabetes, dyslipidemia, anaemia, coronary, thyroid disease, and pulmonary disease have been shown to be correlated with serious COVID-19 findings [1]. Persons with dementia are the most fragile in normal times as they rely on others for their daily life. In a recent review, dementia has been found to increase the risk of morbidity and death, including incidence of respiratory illness, of hospitalising patients. Unfortunately, until now, no research has shown specifically how dementia is linked to COVID-19. This paper seeks to investigate the theoretically related implications of COVID-19 infection with dementia.

KEYWORDS: COVID-19, Pneumonia, Review

BACKGROUND

ASR-CoV-2 is the causal agent of COVID-19 pandemic (Serious Acute Respiratory Syndrome Coronavirus 2) [2,3]. The most prevalent disease is infectious infection, but many organs and systems are vulnerable to various degrees of fibre and respiratory disorder. Cardiovascular effects of COVID-19 are more and more established and the most frequent cardiac abnormality in this environment is the acute myocardial damage with elevated troponin levels. ATT syndrome (TTS) is characterised by an acute ventricular left dysfunction, often secondary to an emotional or physical cause, which is temporary and reversible in most cases. Patients typically feel chest pain and have a rise in the ECG ST section and moderate changes in the serum levels of troponin. Regional wall motion anomalies are observed by cardiac imagery (apical balloning or other forms). The reported TTS incidence ranged from 0.7 to 2.5% in patients with acute coronary syndrome symptoms. There are several recorded cases of TTS between cardiovascular manifestations of COVID-19 which indicate a possible role in the onset of this syndrome of SARS-CoV-2, which, however, still remains unknown [4–7].

The Coronavirus (2019-nCoV) pandemic in the US has grown rapidly, hitting its height in many places, resulting in a lack of personal protective gear, a higher need for breathing systems, and healthcare providers facing difficult choices with shortages of beds and resources. Researchers are anxious to consider the importance of imagery in detecting, diagnosing and treating patients with confirmed or suspected COVID-19 infection. However, in previous publications the role of chest-computing tomography (CT) was described as "normally

unsuitable" and consequently as recommending the sparing use of CT, in early diagnostic, predictive or monitoring of the disease[8–10].

SARS and MERS

The chest x-ray (CXR) has contributed to determining disease path and severity after the 2002 severe acute respiratory syndrome (SARS) and the 2012 Middle East Respiratory syndrome (MERS). The role of clinic variables in the estimation of the severity and mortality of COVID19 diseases, such as age, comorbidities and diverse laboratory and inflammatory parameters, was explored in previous studies.At early stages of the Covid-19 Air Deficiency testing with close control seems fairly stable, for example, of non-invasive help for the breath with high flux of nasal oxygen, persistent positive air pressure (CPAP). The use of NIV was recorded without data on methods and outcomes in some of the previous studies on Covid-19 [11–14].

PNEUMONIA AND COVID

Recently, three studies have documented the routine use of CPAP to inhibit or postpone orotracheal intubation [15–17]. The CPAP loss percentage is between 17 and 50%. Criteria for intuition and patient severity may be the causes for these contradictory results. However, nor arterial hypoglycaemia nor lung density were important predictors of CPAP failure in variance with respiratory distress syndrome consistent with conditions other than pneumonia of the Covid 19 system. In this research, our explanations were that Covid-19 patients may have insufficient diaphragmic control in order to deal with an elevated inspirational elastic load due to the quick increase of dyspnea and the declination of gas exchange in critically ill patients.

Indeed, in large numbers of critically ill patients on ICU entry, and probably due to early multinational impairment and modification of mitochondrial function, diaphragmatic dysfunction is also documented. Ultrasound was used to test diaphragmatic activity in various clinical conditions, including respiratory dysfunction that involves non-invasive ventilation. The diaphragm thickening fraction (DTF) was found to interact especially with the muscle's pressure-generating strength, respiratory work and breathing effort [18–20]. Although the diaphragmatic feature ultrasound evaluation was shown to be a viable and reproductive process, no experiments in Covid-19 air loss have yet been performed. Continuing pandemics with a growing number of worldwide infects and deaths with serious acute coronavirus syndrome 2 have been identified as a SARS CoV-2 (COVID-19) agent (SARS-CoV-2). In the clinical presentation, COVID-19 is variable. While certain patients are asymptomatic, there may be symptoms of fever, dry coss, and dyspnea, causing ICU and death. To date, the viral nucleic acid RT-PCR norm in the real-time diagnosis of COVID-19 is well-known. The rare COVID-19 pandemic contingency and possible pitfalls of accelerated RT-PCR tracking have made high-resolution computer tomography (HRCT) a potential strategy for referring doctors to the clinic. Worldwide consensus statements and guidelines on the role of the imagery in the diagnesis and care of suspicious or diagnoses COVID-19 patients were provided by radiological groups. For those with moderate respiratory problems, RT-PCR positivity, or low-to-high odds, RT-PCR COVID-19 tests are indicated for serious imaging and co-morbidities, such as cardiovascular disease, diabetes mellitus, chronic respiratory disease, arterial hypertension and immune compromising. HRCT would provide a basis for comparison and predicting potential comorbidity-related abnormalities that will thus impact the treatment and follow-up strategy [1,2,21–24].

Over the last few months a variety of studies have concentrated on COVID-19 pneumonia diagnosis, key and auxiliary HRCT characteristics and atypical trends for imaging. As we are aware, a variety of studies have assessed whether the clinical path of HRCT can be predicted by means of individual outcomes (for example, convergence, air bronchogram, central lung inference, pleural exercises and well-ventilated lung parenchyma percentages) or combination

results (e.g., computed tomography [CT] severity score). We were therefore attempting to contribute to the advancement of disease information in determining the predictive role of HRCT in the disease's early stage [3].

DISCUSSION

The epidemic of COVID-19 threatens to endanger the world's health and life. A computer-aided (CAD) framework for the localization and separation of COVID-19 automatically from the community-acquired pneumonia (CAP) in chest X-rays is an immediate priority to improve and validate. It is also an immediate priority. The purpose of this study therefore is to build and test an effective and accurate deep learning software which helps radiologists to identify and locate COVID-19 automatically [25–27]. From open camera data and from the Xiangya hospital a retrospective X-ray image data collection has been compiled and subdivided into a training and a research category. The suggested structure of the CAD consists of two phases for DL's, the DL-DR and the DL-DL. For discrimination in COVID-19, the first DL was designed to strip lung functionality from chest X-ray radiographs and trained with 3548 chest X-rays. The second DL was prepared with 406-pixel patches to identify and assign to known radiographs in the left lung, right lung, or bipulmonary. The robustness of the model was assessed by radiographs of CAP and safe controls. Compared to discrimination and position results by the radiologists, the accuracy of discrimination COVID-19 using discrimination-DL was 98,71%, while localization accuracy with place-DL was 93,03% [28–32].

REFERENCES:

[1] Kottlors J, Große Hokamp N, Fervers P, et al. Early extrapulmonary prognostic features in chest computed tomography in COVID-19 pneumonia: Bone mineral density is a relevant predictor for the clinical outcome - A multicenter feasibility study. *Bone*. 2021;144. doi:10.1016/j.bone.2020.115790

[2] Titi L, Magnanimi E, Mancone M, et al. Fatal Takotsubo syndrome in critical COVID-19 related pneumonia. *Cardiovasc Pathol*. 2021;51. doi:10.1016/j.carpath.2020.107314

[3] Hariyanto TI, Putri C, Arisa J, Situmeang RF V, Kurniawan A. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis. *Arch Gerontol Geriatr*. 2021;93. doi:10.1016/j.archger.2020.104299

[4] Al-Smadi AS, Bhatnagar A, Ali R, Lewis N, Johnson S. Correlation of chest radiography findings with the severity and progression of COVID-19 pneumonia. *Clin Imaging*. 2021;71:17-23. doi:10.1016/j.clinimag.2020.11.004

[5] Grodecki K, Lin A, Razipour A, et al. Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19. *Metabolism*. 2021;115. doi:10.1016/j.metabol.2020.154436

[6] Corradi F, Vetrugno L, Orso D, et al. Diaphragmatic thickening fraction as a potential predictor of response to continuous positive airway pressure ventilation in Covid-19 pneumonia: A single-center pilot study. *Respir Physiol Neurobiol*. 2021;284. doi:10.1016/j.resp.2020.103585

[7] Lee MH, Verde F, Johnson PT, Fishman EK. Unsuspected COVID-19 pneumonia suggests need for higher level of personal protective equipment usage during routine radiologic examinations: Two case reports. *Radiol Case Reports*. 2021;16(2):221-223. doi:10.1016/j.radcr.2020.11.034

[8] Hernández A, Viñals M, Pablos A, et al. Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study. *Int Immunopharmacol*. 2021;90. doi:10.1016/j.intimp.2020.107261

[9] Chen R, Lovas A, Krüger-Ziolek S, Benyó B, Möller K. EIT Based Time Constant Analysis to Determine Different Types of Patients in COVID-19 Pneumonia. In: Jarm T. Cvetkoska A. M-KSMD, ed. *IFMBE Proceedings*. Vol 80. Springer Science and Business Media Deutschland GmbH; 2021:462-469. doi:10.1007/978-3-030-64610-3_52

[10] van der Sar - van der Brugge S, Talman S, de Winter LJM, et al. Pulmonary function and health-related quality of life after COVID-19 pneumonia. *Respir Med*. 2021;176. doi:10.1016/j.rmed.2020.106272

[11] Foust AM, Winant AJ, Chu WC, Das KM, Phillips GS, Lee EY. Pediatric SARS, H1N1, MERS, EVALI, and now coronavirus disease (COVID-19) Pneumonia: What radiologists need to know. *Am J Roentgenol*. 2020;215(3):736-744. doi:10.2214/AJR.20.23267

[12] George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. *Thorax*. 2020;75(11):1009-1016. doi:10.1136/thoraxjnl-2020-215314

[13] Yang J-W, Yang L, Luo R-G, Xu J-F. Corticosteroid administration for viral pneumonia: COVID-19 and beyond. *Clin Microbiol Infect*. 2020;26(9):1171-1177. doi:10.1016/j.cmi.2020.06.020

[14] Ma X, Liang M, Ding M, et al. Extracorporeal membrane oxygenation (ECMO) in critically Ill patients with coronavirus disease 2019 (COVID-19) pneumonia and acute respiratory distress syndrome (ARDS). *Med Sci Monit*. 2020;26. doi:10.12659/MSM.925364

[15] Zheng Z, Ma N, Li L, Jiang D. Efficacy of traditional chinese medicine for covid-19 pneumonia: Two case reports. *J Chinese Med*. 2020;2020(124):37-42. https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094179761&partnerID=40&md5=56f6177d458151b7da814a3a6bf0014e.

[16] Xiao X, Zhu X, Fu S, Hu Y, Li X, Xiao J. Psychological impact of healthcare workers in China during COVID-19 pneumonia epidemic: A multi-center cross-sectional survey investigation. *J Affect Disord*. 2020;274:405-410. doi:10.1016/j.jad.2020.05.081

[17] Pendower L, Benedetti G, Breen K, Karunanithy N. Catheter-directed thrombolysis to treat acute pulmonary thrombosis in a patient with COVID-19 pneumonia. *BMJ Case Rep*. 2020;13(8). doi:10.1136/bcr-2020-237046

[18] Millán-Onte J, Millan W, Mendoza LA, et al. Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. *Ann Clin Microbiol Antimicrob*. 2020;19(1). doi:10.1186/s12941-020-00358-y

[19] Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*. 2020;14(1). doi:10.5582/BST.2020.01047

[20] Ibrahimagić OĆ, Kunić S. Comment on an article: "High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia." *Med Hypotheses*. 2020;145. doi:10.1016/j.mehy.2020.110338

[21] Wiltshire E, Peña AS, MacKenzie K, Shaw G, Couper J. High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia. *Med Hypotheses*. 2020;143. doi:10.1016/j.mehy.2020.110142
[22] Petrakis V, Panagopoulos P, Papazoglou D, Papanas N. Diabetes Mellitus and Hypertension as Major Risk Factors of Mortality from Covid-19 Pneumonia. *Exp Clin Endocrinol Diabetes*. 2020. doi:10.1055/a-1325-0381
[23] Parambil J V, Abdulrahman R, Al-Shokri S. A 73-year-old man with a history of hypertension and ischemic heart disease who presented with pain in the right flank as a symptom of covid-19 pneumonia. *Am J Case Rep*. 2020;21:1-4. doi:10.12659/AJCR.925771
[24] Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. *JRAAS - J Renin-Angiotensin-Aldosterone Syst*. 2020;21(2). doi:10.1177/1470320320926899
[25] Kanoore Edul VS, Caminos Eguillor JF, Ferrara G, et al. Microcirculation alterations in severe COVID-19 pneumonia. *J Crit Care*. 2021;61:73-75. doi:10.1016/j.jcrc.2020.10.002
[26] Sakr Y, Giovini M, Leone M, et al. The clinical spectrum of pulmonary thromboembolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A European case series. *J Crit Care*. 2021;61:39-44. doi:10.1016/j.jcrc.2020.09.021
[27] Wang Z, Xiao Y, Li Y, et al. Automatically discriminating and localizing COVID-19 from community-acquired pneumonia on chest X-rays. *Pattern Recognit*. 2021;110. doi:10.1016/j.patcog.2020.107613
[28] Bozzi G, Mangioni D, Minoia F, et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. *J Allergy Clin Immunol*. 2020. doi:10.1016/j.jaci.2020.11.006
[29] Anai M, Akaike K, Iwagoe H, et al. Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia. *Respir Investig*. 2020. doi:10.1016/j.resinv.2020.10.009
[30] Huang Z, Liu X, Wang R, et al. FaNet: fast assessment network for the novel coronavirus (COVID-19) pneumonia based on 3D CT imaging and clinical symptoms. *Appl Intell*. 2020. doi:10.1007/s10489-020-01965-0
[31] Li X, Lin H, Wang Q, Cui L, Luo H, Luo L. Chemical composition and pharmacological mechanism of shenfu decoction in the treatment of novel coronavirus pneumonia (COVID-19). *Drug Dev Ind Pharm*. 2020;46(12):1947-1959. doi:10.1080/03639045.2020.1826510
[32] Ghahramani-Asl R, Porouhan P, Mehrpouyan M, et al. Feasibility of Treatment Planning System in Localizing the COVID-19 Pneumonia Lesions and Evaluation of Volume Indices of Lung Involvement. *Dose-Response*. 2020;18(3). doi:10.1177/1559325820962600